The Dexcom brand is seen on a smartphone display and within the background.
Pavlo Gonchar | SOPA Photographs | Lightrocket | Getty Photographs
Shares of Dexcom tumbled greater than 36% in after-hours buying and selling Thursday after the diabetes administration firm launched second-quarter outcomes that missed analysts’ expectations for income and provided weak steering.
That is breaking information. Please refresh for updates.
